Skip to main content
for people ages 7–15
at San Francisco, California and other locations
study started
estimated completion:
Principal Investigator



The study objective is to demonstrate that home use of Threshold Suspend (TS) is not associated with glycemic deterioration in pediatric patients with type 1 diabetes, as measured by change in A1C.

Official Title

Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System in Pediatric Patients With Type 1 Diabetes


This study is a longitudinal, multi-center trial that aims to observe the Threshold Suspend (TS) feature with a sensor-augmented insulin pump in patients 7-15 years with Type 1 diabetes. The study will measure the change in A1C from baseline over a period of one year while subjects are wearing the study pump.


Type 1 Diabetes Pediatric Threshold Suspend Sensor augmented pump


You can join if…

Open to people ages 7–15

  1. Subject is age 7 to 15 at time of screening
  2. Subject has been diagnosed with type 1 diabetes mellitus and must have been diagnosed for at least one year prior to screening
  3. Subject is currently transitioning from pump therapy, with or without continued glucose monitoring (CGM), to the 530G insulin pump system.
  4. Subject is willing to perform greater than or equal to 4 finger stick blood glucose measurements daily
  5. Subject is willing to perform required sensor calibrations
  6. Subject is willing to wear the system (Pump, glucose sensors, meter) continuously throughout the study
  7. Subject is willing to upload data every 21 days from the study pump
  8. Subject must have Internet access and access to a computer system that meets the requirements for uploading the pumps. This may include use of family or friend's computer system with Internet access.
  9. Subject is using either Humalog or Novolog at time of Screening and plans to use either of those insulins throughout the study

You CAN'T join if...

  1. Subject is actively participating in an investigational study (drug or device)wherein he/she is receiving treatment from an investigational study drug or investigational study device.
  2. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study
  3. Subject is being treated for hyperthyroidism at time of screening
  4. Subject has an abnormality (>1.8mg/dL) in creatinine at time of screening visit
  5. Subject has an abnormality (out of reference range) in thyroid-stimulating hormone(TSH) at time of screening visit; If TSH is out of range, Free T3 and Free T4 will be tested; subject may be included with TSH out of range as long as Free T3 and Free T4 are in normal reference range.
  6. Subject has taken any oral, injectable, or IV steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
  7. Subject is currently abusing illicit drugs
  8. Subject is currently abusing prescription drugs
  9. Subject is currently abusing alcohol
  10. Subject is using pramlintide (Symlin) at time of screening
  11. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
  12. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
  13. Subject diagnosed with current eating disorder such as anorexia or bulimia
  14. Subject has been diagnosed with chronic kidney disease that results in chronic anemia
  15. Subject is on dialysis
  16. Subject is already on a 530G system with CGM for 8 days or more.


  • Stanford University
    Stanford, California, 94305, United States
  • Sutter Institute for Medical Research Excellence in Diabetes and Endocrinology
    Sacramento, California, 95821, United States
  • Children's Hospital Los Angeles
    Los Angeles, California, 90027, United States
  • SoCal Diabetes
    Torrance, California, 90505, United States
  • Children's Hospital of Orange County
    Orange, California, 92868, United States
  • The Pediatric and Endocrine Diabetes Specialists
    Las Vegas, Nevada, 89148, United States


in progress, not accepting new patients
Start Date
Completion Date
Medtronic Diabetes
Lead Scientist
Saleh Adi
Study Type
Last Updated
January 1, 2017